Cocrystal Pharma announced that its oral protease inhibitor CDI-988 was featured at ICAR 2026, highlighting completed enrollment in a Phase 1b norovirus human challenge study.
Key takeaways
CDI-988, an oral protease inhibitor, received FDA Fast Track designation for norovirus treatment and prophylaxis.
Phase 1b human challenge study (NCT07198139) has fully enrolled its first cohort to establish infectivity rates.
Completed Phase 1 study demonstrated CDI-988 was generally safe and well tolerated at doses up to 1,200 mg.
CDI-988 is designed to target the highly conserved region of the 3CL protease across all known norovirus strains.